Intervacc and the Karolinska Institutet extends contract for the development of innovative animal health vaccines
Stockholm, August 15, 2024 –Intervacc AB (publ) and the Karolinska Institute, KI, announce that they have extended their collaboration to develop a new generation of animal health vaccines using recombinant fusion proteins. The three-year extension means that the research group at the Karolinska Institutet, led by Professor Birgitta Henriques Normark, continues to be part of the successful collaboration between the KI, the Swedish University of Agricultural Sciences (SLU) and Intervacc. This collaboration has led to the development of Strangvac, a vaccine against the streptococcal infection